Skip to main content
Caplight Logo









BlueSphere Bio

BlueSphere Bio

Private
Pittsburgh, PennsylvaniaHealthcare & Life Scienceshttps://bluespherebio.com/

Last Round

Series B

Aug 19, 2021

Total Funding Raised

$115M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

BlueSphere Bio is a biotechnology company that develops personalized T-cell therapies for cancer treatment using its proprietary TCXpress and NeoXPress platforms.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

TCR T-cell therapycell therapyTCR discovery platformcancer immunotherapyleukemia therapyadoptive cell therapyneoantigen discoveryclinical-stage biotechhematologic malignanciesprecision medicinehigh-throughput screeningsolid tumor therapyacute myeloid leukemiaNPM1 mutationHA-1 antigen

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BlueSphere Bio Comparables

Compare BlueSphere Bio with similar companies based on industry and business-model similarity.

BlueSphere Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
T-Therapeutics
83%
3T Biosciences
82%
Enara Bio
80%

BlueSphere Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BAug 19, 2021
Series AOct 1, 2018

Key People

Founding team and executive leadership

Chris Caracciolo

Chief Financial Officer

Executive Team

BlueSphere Bio Investors

Notable investors and investment history

BlueSphere Bio investors
InvestorRounds
UPMC EnterprisesSeries A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 30% MoM.

  • Aug 3, 2026

    Open roles increased to 28, 2.1x the trailing average.

BlueSphere Bio Filings

Explore SEC and related filing metadata, where available.

BlueSphere Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about BlueSphere Bio's valuation, stock price, and market status.

Is BlueSphere Bio a public or private company?

BlueSphere Bio is a private company.

What is the current stock price of BlueSphere Bio?

BlueSphere Bio is a private company with no public stock price. No recent secondary market data is available.

How much is BlueSphere Bio worth (valuation)?

Valuation information for BlueSphere Bio is not publicly available.

Can I buy BlueSphere Bio stock?

BlueSphere Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was BlueSphere Bio's last funding round?

BlueSphere Bio's most recent funding round was Series B on August 19, 2021.

Who are the main investors in BlueSphere Bio?

Key investors in BlueSphere Bio include UPMC Enterprises.

Will BlueSphere Bio IPO soon?

No public IPO plans have been announced for BlueSphere Bio.

How can I track BlueSphere Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor BlueSphere Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersPittsburgh, Pennsylvania
Employee Range24
Year Founded2017
Last FundingAug 19, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?